The Patent Finder

Shanghai Pharmaceuticals Holding Co., Ltd.

11 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

1
Ending by 2030
Jun 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications (US 10,344,035) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof (US 10,519,150) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Sep 8, 2027
    The maintenance fee for Nitrogen-containing saturated heterocyclic compound (US 9,278,944) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,975,252Morpholine Derivative
In force
 · High confidence
In forceHigh confidence
US 9,278,944Nitrogen-containing saturated heterocyclic compound
In force
 · USPTO record
In forceUSPTO record
US 10,155,731Nitrogen-Containing Saturated Heterocyclic Compound
In force
 · Low confidence
In forceLow confidence
US 9,556,159Renin inhibitor
In force
 · USPTO record
In forceUSPTO record
US 10,344,035Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications
In force
 · USPTO record
In forceUSPTO record
US 10,519,150Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
In force
 · USPTO record
In forceUSPTO record
US 11,578,074Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
In force
 · USPTO record
In forceUSPTO record
US 11,643,428Therapeutic Drug for Neurodegenerative Disease and Application Thereof
In force
 · High confidence
In forceHigh confidence
US 11,578,092Novel Compound for Preventing or Treating Neurodegenerative Disease and Application Thereof
In force
 · High confidence
In forceHigh confidence
US 12,612,408Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 4 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited